Evidence map›Paper›PMID 41699841›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2026

Role of

Hatice Uysal, Aziz Gültekin, Nil Güler, Nilay Şen Türk, Fikri Selçuk Şimşek, Tarık Şengöz, Doğangün Yüksel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Prognostic value of baselineFrontiers in nuclear medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hatice UysalAntalya City Hospital, Clinic of Nuclear Medicine, Antalya, TürkiyeORCID 0009-0006-1747-0772
Aziz GültekinPamukkale University Faculty of Medicine, Department of Nuclear Medicine, Denizli, TürkiyeORCID 0000-0002-0311-8077
Nil GülerPamukkale University Faculty of Medicine, Department of Hematology, Denizli, TürkiyeORCID 0000-0003-0604-6475
Nilay Şen TürkPamukkale University Faculty of Medicine, Department of Medical Pathology, Denizli, TürkiyeORCID 0000-0002-8294-558X
Fikri Selçuk ŞimşekPamukkale University Faculty of Medicine, Department of Nuclear Medicine, Denizli, TürkiyeORCID 0000-0001-9906-0617
Tarık ŞengözPamukkale University Faculty of Medicine, Department of Nuclear Medicine, Denizli, TürkiyeORCID 0000-0003-2621-7585
Doğangün YükselSağlık Hospital, Clinic of Nuclear Medicine, Denizli, TürkiyeORCID 0000-0003-0983-2834

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to evaluate the predictive value of volumetric metabolic parameters and their longitudinal changes from Materials and Methods: Metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum standardized uptake value (SUVmax) were calculated from the baseline, interim, and post-treatment PET/CT scans of 63 adult patients with HL. Delta (Δ) parameters representing percentage changes were computed. Cox regression and Kaplan-Meier analyses were performed. Receiver operating characteristic curve analysis was applied to determine optimal cut-offs for baseline parameters; median dichotomization was used for delta metrics. Results: Pre-treatment MTV1 was significantly higher in patients with progression (650.98±751.34 vs. 354.15±306.72 cm Conclusion: Baseline volumetric parameters and long-interval metabolic changes are powerful prognostic markers in HL. ΔSUVmax

Indexed as

Fluorodeoxyglucose F18Hodgkin DiseasePositron Emission Tomography Computed TomographyAdolescentAdultFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeYoung AdultFluorodeoxyglucose F18Hodgkin lymphomaMetabolic tumor volumePositron emission tomographyPrognosisTotal lesion glycolysisΔMTVΔSUVmaxΔTLG

Identifiers

PMID41699841
PMCPMC13540399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.